Evidence map›Paper›PMID 35953581›Full record

ReviewNature metabolism2022

Every islet matters: improving the impact of human islet research.

Anna L Gloyn, Mark Ibberson, Piero Marchetti, Alvin C Powers, Patrik Rorsman, Maike Sander, Michele Solimena

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in Nature metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Lessons from a model: early glucagon dysfunction in type 2 diabetes.Pflugers Archiv : European journal of physiology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 6 countries.

Anna L GloynDepartment of Pediatrics, Division of Endocrinology & Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA. agloyn@stanford.edu.ORCID http://orcid.org/0000-0003-1205-1844
Mark IbbersonVital-IT, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-3152-5670
Piero MarchettiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alvin C PowersVanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-1941-5786
Patrik RorsmanOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7578-0767
Maike SanderDepartment of Pediatrics, Pediatric Diabetes Research Center, University of California, San Diego, San Diego, CA, USA.
Michele SolimenaDepartment of Molecular Diabetology, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany. Michele.Solimena@uniklinikum-dresden.de.
Klinik und Poliklinik für Psychotherapie und Psychosomatik · DESIB Swiss Institute of Bioinformatics · CHStanford Medicine · USUniversity of California San Diego · USUniversity of Oxford · GBUniversity of Pisa · ITVA Tennessee Valley Healthcare System · US

Funding

Human Pancreas Analysis Program for Type 1 Diabetes - HPAP-T1DU01DK112217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MARK A. ATKINSON, KLAUS H KAESTNER · 2021 to 2026
$46.8M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Penn integrated Human Pancreas procurement and Analysis ProgramUC4DK112217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R, FELDMAN, MICHAEL D · 2016 to 2020
$17.8M
Integrated Islet Distribution Program (U24) - 2021U24DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Carmella Evans-Molina, Joyce Carol Niland · 2021 to 2026
$17.8M
An interactive resource to generate and provide integrated knowledge of the human pancreasU24DK138512 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Noel P Burtt, Jason Flannick · 2024 to 2026
$9.6M
Bridging the gap between type 2 diabetes GWAS and therapeutic targetsUM1DK126185 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLAUSSNITZER, MELINA C, GLOYN, ANNA LOUISE · 2020 to 2024
$9.5M
Supplement to Integrated Program for Human Pancreas Procurement and AnalysisUC4DK112232 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., POWERS, ALVIN C · 2016 to 2020
$8.4M
The impact of genomic variation on environment-induced changes in pancreatic beta cell statesU01HG012059 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Hannah Kathryn Carter, Kyle Jeffrie Gaulton · 2021 to 2026
$7.5M
Nkx6 gene function in pancreas developmentR01DK068471 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI WORTHAM, MATTHEW · 2004 to 2024
$6.6M
Human Pancreas Analysis Program-T2DU01DK123716 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., BOTTINO, RITA · 2019 to 2024
$6.6M
Discovery of Pancreatic Signatures in Type 2 Diabetes MellitusR24DK106755 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAI, LONG, CAPRIOLI, RICHARD M · 2015 to 2019
$6.2M
BLRD VA I01 BX000666Medical Research Council MR/V011979/1NHGRI NIH HHS U01 HG012059NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK068471NIDDK NIH HHS R01 DK078803NIDDK NIH HHS R01 DK114427NIDDK NIH HHS R01 DK122607NIDDK NIH HHS R24 DK106755NIDDK NIH HHS U01 DK085545NIDDK NIH HHS U01 DK105535NIDDK NIH HHS U01 DK112217NIDDK NIH HHS U01 DK120429NIDDK NIH HHS U01 DK123716NIDDK NIH HHS U01 DK123743NIDDK NIH HHS U24 DK098085NIDDK NIH HHS U24 DK138512NIDDK NIH HHS UC4 DK112217NIDDK NIH HHS UC4 DK112232NIDDK NIH HHS UH3 DK122639NIDDK NIH HHS UM1 DK126185Wellcome Trust 200837Wellcome Trust 200837/Z/16/Z
6 · The paper itself

Abstract

Detailed characterization of human pancreatic islets is key to elucidating the pathophysiology of all forms of diabetes, especially type 2 diabetes. However, access to human pancreatic islets is limited. Pancreatic tissue for islet retrieval can be obtained from brain-dead organ donors or from individuals undergoing pancreatectomy, often referred to as 'living donors'. Different protocols for human islet procurement can substantially impact islet function. This variability, coupled with heterogeneity between individuals and islets, results in analytical challenges to separate genuine disease pathology or differences between human donors from experimental noise. There are currently no international guidelines for human donor phenotyping, islet procurement and functional characterization. This lack of standardization means that substantial investments from multiple international efforts towards improved understanding of diabetes pathology cannot be fully leveraged. In this Perspective, we overview the status of the field of human islet research, highlight the challenges and propose actions that could accelerate research progress and increase understanding of type 2 diabetes to slow its pandemic spreading.

Indexed as

Diabetes Mellitus, Type 2Islets of LangerhansIslets of Langerhans TransplantationHumansLiving DonorsPancreas

Identifiers

PMID35953581
PMCPMC11135339
OpenAlexW4292865406

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.